Lunit Cancer Screening

Lunit is a public company that develops medical AI software that helps conquer cancer globally.

Founded 2013

Seattle, United States 320 employees Post-IPO Debt Total: $405.58B AI, Analytics +4

General Information

Company Name Lunit Cancer Screening

Founded Year 2013

Location

Seattle, United States

Founders / Decision Makers

Employees 320

Industries AI, Analytics, Computer Vision +3

Funding Stage Post-IPO Debt

Business Model B2B, SaaS, Platform

Revenue Model Subscription, Usage Based, Tiered Pricing

Offices as of Nov 2026

Seattle, United States

Social

BounceWatch is an independent company data service, not affiliated with Lunit Cancer Screening. To contact Lunit Cancer Screening, visit lunit.io.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Lunit Cancer Screening compare?

A PDF of Lunit Cancer Screening and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Lunit Cancer Screening soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

From the desk

Is Lunit Cancer Screening on your competitive set?

Our desk can watch it and brief you on every move: hiring, funding, leadership, product and pricing.

Book a 7-day Readout

Discover More

United States Market

Market Signals All Companies

Industry Signals All Companies in United States

Lunit Cancer Screening Alternatives

All Signals Trend Reports

Recorded by Bounce Watch from public sources. Every entry below carries the date we observed it, and when we have not looked recently the page says so rather than leaving silence to imply nothing happened.

Event Participation Nov 04, 2026

Lunit's AI technology will be featured in the BIEDX Mammography with AI Masterclass 2026 presented by Dr. Niketa Chotai.

New Partnership Nov 03, 2026

Lunit Cancer Screening is bringing its innovative mammogram AI software into clinical use for earlier breast cancer detection.

Lunit Cancer Screening a competitor of yours? Have our desk watch it

About Lunit Cancer Screening

Lunit Cancer Screening is a trailblazer in the domain of medical AI, with a mission to "Conquer Cancer through AI". Founded in 2013, this United States-headquartered company has emerged as a leader in developing AI-driven software solutions specifically for cancer screening and treatment.

Lunit specializes in empowering healthcare professionals to significantly enhance diagnostic accuracy. Its flagship product suite, Lunit AI Suite for Radiology, features lauded innovations like Lunit INSIGHT CXR for chest x-rays, and Lunit INSIGHT MMG for mammography, validated in over 100 peer-reviewed publications. The company's technology is currently deployed at more than 3,500+ sites worldwide.

Lunit's growth trajectory received a substantial boost from a recent KRW166.50 billion post-IPO debt investment as of 07 May 2024. This capital injection underscores confidence in Lunit's promise to revolutionize cancer diagnostics globally, marking it as a compelling opportunity for investors interested in cutting-edge health tech.

Business keywords: Medical AI, Cancer Screening, Radiology AI, Medical Imaging Software, Deep Learning Technology, Breast Cancer Screening, Chest X-ray AI, Mammography AI, Digital Breast Tomosynthesis, Medical Imaging Analysis, Healthcare AI, Biomarker Technology, AI-powered Diagnostics, Medical Data Analysis, Clinical Decision Support

Services & Products

Cancer Screening

Precision Oncology

AI-Driven Workflows

Medical Imaging Analysis

Clinical Decision Support

Target Customers

Healthcare Providers Radiologists Biopharma Companies Clinicians Oncology Researchers

Funding Rounds & Investors (11)

View All

Funding Stage	Amount	Investors	Lead Investors	Date
Post IPO Debt	KRW166.50B	-		07 May 2024
Post IPO Equity	$150.00M	-		15 Nov 2023
Post IPO Equity	KRW200.00B	-		24 Aug 2023
Venture Round	$61.00M	10	HealthQuest Capital, Kakao Ventures +8	29 Nov 2021
Series C	$26.00M	1	Guardant Health	19 Jul 2021
Series C	KRW30.00B	7	Kakao Ventures, InterVest Co. +5	31 Dec 2019
Series B	KRW5.00B	1	Fujifilm	30 Nov 2019
Series B	$15.00M	7	Formation 8, Kakao Ventures +5	13 Jul 2018
Series A	KRW3.73B	4	Kakao Ventures, InterVest Co. +2	31 Aug 2016
Series A	$2.00M	3	Formation 8, Kakao Ventures +1	03 Nov 2015

View All 11 Funding Rounds

Lunit Cancer Screening Alternatives & Competitors

View All Alternatives

Lunit Cancer Screening vs

ScreenPoint Medical The Netherlands

The Breast AI Company: Leading the way in early breast cancer detection.

Series C

89 employees

AI, Analytics

Compare Lunit Cancer Screening vs ScreenPoint Medical

Lunit Cancer Screening vs

Hera-MI France

Shaping the future of radiology by making AI & Radiologists working together to improve breast cance...

Non Equity Assistance

22 employees

AI, Biotechnology

Compare Lunit Cancer Screening vs Hera-MI

Lunit Cancer Screening vs

b-rayZ Switzerland

Empower Mammography through Artificial Intelligence

Series A

20 employees

AI, Analytics

Also compare with:

Vara

Kheiron Medical View all alternatives

FAQ About Lunit Cancer Screening

Lunit is a public company that develops medical AI software that helps conquer cancer globally.

Lunit Cancer Screening was founded in 2013.

Lunit Cancer Screening is headquartered in Seattle, United States.

Lunit Cancer Screening operates in AI, Analytics, Computer Vision, Health Care, Medical Devices and Machine Learning. Its work centres on Medical AI, Cancer Screening, Radiology AI and Medical Imaging Software. Its customers include Healthcare Providers, Radiologists and Biopharma Companies.

Lunit Cancer Screening has a B2B, SaaS and Platform business model. Its revenue comes from Subscription, Usage Based and Tiered Pricing.

Lunit Cancer Screening has approximately 320 employees.

Lunit Cancer Screening has completed 11 funding rounds, raising a total of $405.58B. The latest funding stage is Post-IPO Debt.

Lunit Cancer Screening offers: Cancer Screening, Precision Oncology, AI-Driven Workflows, Medical Imaging Analysis, Clinical Decision Support.

Top alternatives and competitors to Lunit Cancer Screening include ScreenPoint Medical, Hera-MI, b-rayZ, CureMetrix, MICA AI Medical. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Lunit Cancer Screening and ScreenPoint Medical are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Lunit Cancer Screening, https://bouncewatch.com/company/lunit-global, updated 6 November 2026. When citing, please name BounceWatch and link this page.

Lunit Cancer Screening

General Information

Discover More

What changed at Lunit Cancer Screening recently?

About Lunit Cancer Screening

Services & Products

Target Customers

Funding Rounds & Investors (11)

Lunit Cancer Screening Alternatives & Competitors

FAQ About Lunit Cancer Screening